XML 19 R10.htm IDEA: XBRL DOCUMENT

Certain Financial Statement Caption Information

9 Months Ended

Sep. 30, 2023

Certain Financial Statement Caption Information [Abstract]

Certain Financial Statement Caption Information

4. Certain Financial Statement Caption Information

Short-Term Investments

The following table summarizes the Company’s short-term investments (in thousands):


	Maturity	Amortized		Unrealized		Unrealized			Estimated
	(in years)	Cost		Gains		Losses			Fair Value
September 30, 2023
U.S. treasury securities	1 or less	$	11,936	$	-	$	(12	)	$	11,924
Total		$	11,936	$	-	$	(12	)	$	11,924
December 31, 2022
U.S. treasury securities	1 or less	$	12,006		-		(90	)	$	11,916
Total		$	12,006	$	-	$	(90	)	$	11,916

All of the Company’s available-for-sale securities are available to the Company for use in its current operations. As a result, the Company categorizes all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date. All of the Company’s securities have a maturity within two years of the balance sheet date.

There were no impairments considered other-than-temporary during the periods presented, as it is management’s intention and ability to hold the securities until a recovery of the cost basis or recovery of fair value. Unrealized gains and losses are included in accumulated other comprehensive loss.

Accrued Expenses

Accrued expenses consisted of the following (in thousands):


	September 30,		December 31,
	2023		2022
Clinical development	$	4,368	$	3,253
Accrued payroll and other employee benefits		2,359		2,975
Other accruals		595		472
Income tax		564		-
Non-clinical research		418		465
Accrued interest		-		74
Total accrued expenses	$	8,304	$	7,239